WuXi AppTec DMPK touts TidesID for faster peptide metabolite ID

WuXi AppTec DMPK says its TidesID platform can automate peptide metabolite identification for complex modified molecules, cutting analysis time while improving precision. The company says the system combines LC-HRMS instrumentation, predictive algorithms and manual review to deliver metabolite reports in 10 days or less.

Why it matters: - Peptide drugs can target protein-protein interactions that are hard to address with traditional small molecules. - Metabolite identification is a required step for modified peptides because it helps reveal stability risks, clearance pathways and potential safety issues early. - Faster, more accurate MetID can help developers move peptide candidates forward with fewer analytical delays.

What happened: - WuXi AppTec DMPK introduced the TidesID intelligent interpretation platform for peptide metabolite identification and DMPK profiling. - The platform is designed for cyclic, stapled and other highly modified peptides. - WuXi AppTec says the platform is paired with a unified LC-HRMS workflow for sample preparation, analysis and data processing. - The company says the workflow supports metabolite report turnaround times of 10 days or less.

The details: - Modified peptides can produce a large number of possible cleavage fragments and metabolic soft spots. - Low dosing and weak UV absorption can make peptide metabolites difficult to detect in biological matrices. - Multi-charged ions, dehydration and deamination can create complex mass spectrometry data that legacy software may misread. - TidesID is built to recognize diverse molecular backbones, including linear peptides, cyclic and multi-cyclic structures, stapled variants and unnatural organic groups. - The platform uses algorithms that cover major metabolic pathways and predict likely metabolite structures before fragmentation matching. - The MS1 and MS2 modules match full-scan HRMS data with tandem fragmentation data to identify metabolites without manual guesswork. - WuXi AppTec says internal in vitro plasma testing on an untested molecule labeled "Peptide-1" identified four metabolites. - The platform isolated isomeric single-peptide bond hydrolysis products and mapped the cleavage site tied to the most abundant metabolite, M4.

Between the lines: - The pitch is aimed at a persistent bottleneck in peptide development: too many possible metabolites and too much data for manual interpretation alone. - The company is positioning automation as a way to reduce false positives and shorten the path from exploratory chemistry to decision-making. - The hybrid model still leaves room for expert review, which suggests the software is intended to accelerate, not fully replace, scientific judgment.

What's next: - WuXi AppTec DMPK is betting that faster MetID readouts will help sponsors optimize structure, choose toxicology species and define clearance mechanisms earlier in development. - If the 10-day turnaround holds across more projects, the platform could become a more attractive option for sponsors working on complex peptide modalities.

The bottom line: - WuXi AppTec DMPK is selling TidesID as a faster, more automated way to turn complex peptide metabolite data into actionable development decisions.